These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32487842)

  • 1. Vasopressor use in cardiogenic shock.
    Levy B; Klein T; Kimmoun A
    Curr Opin Crit Care; 2020 Aug; 26(4):411-416. PubMed ID: 32487842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotropes and vasopressors use in cardiogenic shock: when, which and how much?
    Levy B; Buzon J; Kimmoun A
    Curr Opin Crit Care; 2019 Aug; 25(4):384-390. PubMed ID: 31166204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction.
    Levy B; Clere-Jehl R; Legras A; Morichau-Beauchant T; Leone M; Frederique G; Quenot JP; Kimmoun A; Cariou A; Lassus J; Harjola VP; Meziani F; Louis G; Rossignol P; Duarte K; Girerd N; Mebazaa A; Vignon P;
    J Am Coll Cardiol; 2018 Jul; 72(2):173-182. PubMed ID: 29976291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic therapies for acute cardiogenic shock.
    Nativi-Nicolau J; Selzman CH; Fang JC; Stehlik J
    Curr Opin Cardiol; 2014 May; 29(3):250-7. PubMed ID: 24686400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study.
    Levy B; Perez P; Perny J; Thivilier C; Gerard A
    Crit Care Med; 2011 Mar; 39(3):450-5. PubMed ID: 21037469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Norepinephrine versus epinephrine for hemodynamic support in post-cardiac arrest shock: A systematic review.
    Lawson CK; Faine BA; Rech MA; Childs CA; Brown CS; Slocum GW; Acquisto NM; Ray L;
    Am J Emerg Med; 2024 Mar; 77():158-163. PubMed ID: 38150986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The medical treatment of cardiogenic shock: cardiovascular drugs.
    De Backer D; Arias Ortiz J; Levy B
    Curr Opin Crit Care; 2021 Aug; 27(4):426-432. PubMed ID: 33797431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential lessons in cardiogenic shock: epinephrine versus norepinephrine/dobutamine.
    Krenn L; Delle Karth G
    Crit Care Med; 2011 Mar; 39(3):583-4. PubMed ID: 21330855
    [No Abstract]   [Full Text] [Related]  

  • 9. Vasopressor therapy in critically ill patients with shock.
    Russell JA
    Intensive Care Med; 2019 Nov; 45(11):1503-1517. PubMed ID: 31646370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiogenic shock.
    Rackley CE; Russell RO; Mantle JA; Rogers WJ
    Cardiovasc Clin; 1981; 11(3):15-24. PubMed ID: 7214388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressors for acute myocardial infarction complicated by cardiogenic shock.
    Prondzinsky R; Hirsch K; Wachsmuth L; Buerke M; Unverzagt S
    Med Klin Intensivmed Notfmed; 2019 Feb; 114(1):21-29. PubMed ID: 29204662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of equipressor doses of norepinephrine, epinephrine, and phenylephrine on septic myocardial dysfunction.
    Ducrocq N; Kimmoun A; Furmaniuk A; Hekalo Z; Maskali F; Poussier S; Marie PY; Levy B
    Anesthesiology; 2012 May; 116(5):1083-91. PubMed ID: 22407285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine versus norepinephrine in the treatment of shock.
    Nathan Coxford R; Lang E; Dowling S
    CJEM; 2011 Nov; 13(6):395-7. PubMed ID: 22436478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure.
    Møller MH; Claudius C; Junttila E; Haney M; Oscarsson-Tibblin A; Haavind A; Perner A
    Acta Anaesthesiol Scand; 2016 Nov; 60(10):1347-1366. PubMed ID: 27576362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressor agents in shock.
    Moyer JH; Mills LC
    Am J Nurs; 1975 Apr; 75(4):620-5. PubMed ID: 1039254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catecholamines for shock: the quest for high-quality evidence.
    Myburgh JA
    Crit Care Resusc; 2007 Dec; 9(4):352-6. PubMed ID: 18052900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of Inotropes and Inopressors for Effective Utilization in Patients With Acute Decompensated Heart Failure.
    Nandkeolyar S; Ryu R; Mohammad A; Cordero-Caban K; Abramov D; Tran H; Hauschild C; Stoletniy L; Hilliard A; Sakr A
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):336-345. PubMed ID: 34117179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine versus norepinephrine as the first-line vasopressor in the treatment of cardiogenic shock.
    Na SJ; Yang JH; Ko RE; Chung CR; Cho YH; Choi KH; Kim D; Park TK; Lee JM; Song YB; Choi JO; Hahn JY; Choi SH; Gwon HC
    PLoS One; 2022; 17(11):e0277087. PubMed ID: 36327286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vasopressin as a rescue vasopressor agent. Treatment of selected cardiogenic shock states].
    Mayr VD; Luckner G; Jochberger S; Wenzel V; Hasibeder WR; Dünser MW
    Anaesthesist; 2007 Oct; 56(10):1017-20, 1022-3. PubMed ID: 17594065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies regarding choice of vasopressor therapy for management of septic shock in animals.
    Silverstein DC; Beer KA
    J Vet Emerg Crit Care (San Antonio); 2015; 25(1):48-54. PubMed ID: 25655726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.